MyMD Pharmaceuticals, Inc. - Common Stock (NQ:MYMD)

1.820 UNCHANGED

Last Price Updated: 3:38 PM EDT, Jul 23, 2024 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Press Releases about MyMD Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 Next >

TNF Pharmaceuticals (Formerly MyMD Pharmaceuticals) Begins Trading Under New Nasdaq Stock Symbol “TNFA” Effective Before Market Open Today

July 24, 2024

From TNF Pharmaceuticals, Inc.

Via Business Wire

MyMD Pharmaceuticals Announces Corporate Rebranding to New Name TNF Pharmaceuticals, Inc.

July 22, 2024

From MyMD Pharmaceuticals, Inc.

Via Business Wire

MyMD Pharmaceuticals Appoints Accomplished Biopharmaceutical Leader and Current Board Member, Mitchell Glass, M.D. as President and Chief Medical Officer

June 17, 2024

From MyMD Pharmaceuticals, Inc.

Via Business Wire

Intelligent Bio Solutions Inc. (NASDAQ: INBS) Advancing US FDA Process, Featured Among Top Health Care Movers

May 31, 2024

Via AB Newswire

MyMD Pharmaceuticals Secures Strategic Investments

May 21, 2024

From MyMD Pharmaceuticals, Inc.

Via Business Wire

Ladenburg Thalmann, Esteemed Wall Street Long-Standing Stalwart Since 1876, Advocates ‘Buy’ for Intelligent Bio, Precision Bio, and More: VTAK, INBS, LASE, MYMD, RVSN

April 09, 2024

Via AB Newswire

MyMD Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement for Continued Listing

March 05, 2024

From MyMD Pharmaceuticals, Inc.

Via Business Wire

MyMD Pharmaceuticals Announces Reverse Stock Split to Maintain Nasdaq Listing

February 13, 2024

From MyMD Pharmaceuticals, Inc.

Via Business Wire

MyMD Pharmaceuticals Plans FDA-Cleared Phase 2 Clinical Trial of MYMD-1 in Rheumatoid Arthritis

December 06, 2023

From MyMD Pharmaceuticals, Inc.

Via Business Wire

MyMD Announces Preclinical Study Results Showing Novel Cannabidiol Analog, Supera-CBD™, Reduced Acute Inflammatory Pain

October 19, 2023

From MyMD Pharmaceuticals, Inc.

Via Business Wire

MyMD Pharmaceuticals to Present Updated Statistically Significant Phase 2 Data for MYMD-1, Potential TNF-α Market Disrupter, at BioFuture 2023

October 04, 2023

From MyMD Pharmaceuticals, Inc.

Via Business Wire

FDA Accepts MyMD Pharmaceuticals’ Investigational New Drug Application (IND) for Phase 2 Study of oral TNF-α inhibitor MYMD-1® in Rheumatoid Arthritis (RA)

August 14, 2023

From MyMD Pharmaceuticals, Inc.

Via Business Wire

MyMD Pharmaceuticals to Hold Conference Call Today to Discuss Phase 2 Trial Results

August 02, 2023

From MyMD Pharmaceuticals, Inc.

Via Business Wire

MyMD Pharmaceuticals Reports Statistically Significant Positive Topline Phase 2 Results for Next Generation Oral TNF-α Inhibitor MYMD-1® in Sarcopenia/Age-Related Frailty

July 31, 2023

From MyMD Pharmaceuticals, Inc.

Via Business Wire

MyMD Pharmaceuticals® Provides Dosing Update on Phase 2 Multi-Center Clinical Trial of MYMD-1® as a Therapy for Delaying Aging and Extending Healthy Lifespan

April 12, 2023

From MyMD Pharmaceuticals, Inc.

Via Business Wire

MyMD Pharmaceuticals® and Charles River Present Positive Data for Next Generation, Oral TNF-α Inhibitor MYMD-1® in Rheumatoid Arthritis

March 20, 2023

From MyMD Pharmaceuticals, Inc.

Via Business Wire

MyMD Joins LOT Network in Effort to Protect Company and Shareholders from Patent Trolls

March 08, 2023

From MyMD Pharmaceuticals, Inc.

Via Business Wire

MyMD Announces U.S. Drug Enforcement Administration (DEA) Determines Supera-CBD™ is not a Controlled Substance or Listed Chemical

March 02, 2023

From MyMD Pharmaceuticals, Inc.

Via Business Wire

MyMD Pharmaceuticals® Announces Upcoming Presentation of Preclinical Rheumatoid Arthritis Data for Oral TNF-α Inhibitor MYMD-1® at the Society of Toxicology 2023 Annual Meeting

February 28, 2023

From MyMD Pharmaceuticals, Inc.

Via Business Wire

MyMD Announces $15 Million Offering with Existing Investors

February 21, 2023

From MyMD Pharmaceuticals, Inc.

Via Business Wire

ADDING MULTIMEDIA MyMD Pharmaceuticals® to Present Data on Oral TNF-a Inhibitor MYMD-1® at the British Society for Immunology (BSI) Congress 2022

December 06, 2022

From MyMD Pharmaceuticals, Inc.

Via Business Wire

MyMD Pharmaceuticals® Announces Upcoming Presentation of Late-Breaking Data for MYMD-1® at the 2022 British Society for Immunology (BSI) Congress

November 17, 2022

From MyMD Pharmaceuticals, Inc.

Via Business Wire

MyMD Pharmaceuticals Announces Publication of Phase 1 Data for oral TNF-alpha Inhibitor MYMD-1® in Peer-Reviewed Journal Drug Research

November 14, 2022

From MyMD Pharmaceuticals, Inc.

Via Business Wire

MyMD Pharmaceuticals® Provides Dosing Update on Phase 2 Multi-Center Clinical Trial of MYMD-1® as a Therapy for Delaying Aging and Extending Healthy Lifespan

September 20, 2022

From MyMD Pharmaceuticals, Inc.

Via Business Wire

MyMD Pharmaceuticals Receives Grant From European Patent Office for Supera-CBD™ Compound

August 30, 2022

From MyMD Pharmaceuticals, Inc.

Via Business Wire

Data Showing MyMD Pharmaceuticals’ MYMD-1® May Extend Life and Improve Health Published in the Journal of Gerontology: Biological Sciences

August 03, 2022

From MyMD Pharmaceuticals, Inc.

Via Business Wire

MyMD Pharmaceuticals® Advances Phase 2 Multi-Center Clinical Trial of MYMD-1® as a Therapy for Delaying Aging and Extending Healthy Lifespan

July 26, 2022

From MyMD Pharmaceuticals, Inc.

Via Business Wire

MyMD Pharmaceuticals to Collaborate with Bascom Palmer Eye Institute to Study MYMD-1 in Ophthalmic Conditions

July 12, 2022

From MyMD Pharmaceuticals, Inc.

Via Business Wire

MyMD Pharmaceuticals Advances Phase 2 Multi-Center Clinical Trial of MYMD-1 as a Therapy for Delaying Aging and Extending Healthy Lifespan

June 21, 2022

From MyMD Pharmaceuticals, Inc.

Via Business Wire

MyMD Pharmaceuticals Accelerates Pace of New Patient Dosing in Phase 2 Clinical Trial of MYMD-1 as a Therapy for Delaying Aging and Extending Healthy Lifespan

April 05, 2022

From MyMD Pharmaceuticals, Inc.

Via Business Wire

< Previous 1 2 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.